A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers

Daniel M Halperin¹, Alexandria T Phan², Ana O Hoff³, Marie Aaron¹, James C Yao¹* and Paulo M Hoff⁴

Abstract

Background: Patients with advanced endocrine cancers, such as adrenocortical carcinoma and medullary thyroid carcinoma, have few well-validated therapeutic options. Pre-clinical studies have suggested potential activity of imatinib in these tumors. We therefore sought to establish a safe, novel treatment regimen combining imatinib with cytotoxic chemotherapy for future study in endocrine cancers.

Methods: A standard 3 + 3 dose-escalation design was used with a 21-day cycle, including imatinib on days 1–21, dacarbazine on days 1–3, and capecitabine on days 1–14.

Results: Twenty patients were treated. The most frequent toxicities were edema and fatigue, with dose-limiting fatigue and dyspnea. The recommended phase II regimen is dacarbazine 250 mg/m² daily on day 1–3, capecitabine 500 mg/m² twice daily on days 1–14, and imatinib 300 mg daily on days 1–21 of a 21-day cycle. Interestingly, responses were seen in patients with adrenocortical carcinoma, with 1 of 6 patients experiencing a partial response and a second experiencing a minor response, with progression-free survival of 8.8 and 6.4 months, respectively.

Conclusions: The regimen of imatinib, dacarbazine, and capecitabine is well-tolerated. It may have some activity in adrenocortical carcinoma, and further study of this combination or its components may be beneficial for this disease with limited treatment options.

Trial registration: ClinicalTrials.gov identifier NCT00354523, registered July 18, 2006.

Background

Endocrine cancers are a heterogeneous group of malignancies. Adrenocortical carcinoma (ACC) and medullary thyroid carcinoma (MTC) are challenging cancers to treat if metastatic or unresectable, and few chemotherapy regimens have proven effective for advanced disease.

Medullary thyroid carcinoma (MTC) is a rare tumor arising from the parafollicular C cells of the thyroid gland [1]. Approximately 75% of these tumors are sporadic and 25% are hereditary, associated with the multiple endocrine neoplasia type 2 syndrome (MEN2) [2]. Multiple endocrine neoplasia type 2 is an autosomal dominant syndrome caused by germline activating mutations of the RET proto-oncogene which encodes for RET, a receptor tyrosine kinase that modulates C cell proliferation and apoptosis [3–5]. Patients with sporadic MTC do not carry germline RET mutations, but 40% of their tumors carry a somatic RET mutation, most commonly involving exon 16, conferring a more aggressive phenotype [6–9]. In vitro and in vivo studies of the most common germline and somatic RET mutations have established their role in oncogenesis [10–13]. In vitro studies using a MTC cell line with a RET codon 634 mutation demonstrated growth inhibition with imatinib, offering some hope that the drug may have efficacy in this tumor [14].

Systemic cytotoxic chemotherapy for advanced MTC has shown limited tumor response efficacy. Small trials studying dacarbazine, 5-fluorouracil, and doxorubicin [15–20], used alone or in combination, have demonstrated partial biochemical and tumor responses in 10-20% of patients. More recently, inhibitors of the RET kinase, such as vandetanib [21] and cabozantinib [22], have shown evidence of significant progression-free survival benefit, and hence are FDA-approved for the treatment of patients with advanced MTC.

Adrenocortical carcinoma (ACC) is another rare malignancy of neuroectodermal origin with limited therapeutic options. It has an annual incidence of 1–2 cases
per million population [23,24], and a median overall survival that decreases dramatically as a function of clinical stage, ranging from over 10 years for stage I disease to less than 6 months with advanced stage [24]. Most cases are sporadic, but associations have been demonstrated with Li Fraumeni syndrome, Beckwith-Wiedemann syndrome, and MEN 1 [25,26]. While mitotane has been the mainstay of therapy since it was demonstrated to reduce serum and urine steroid concentrations in over 70% of patients in 1966 [27], high-quality clinical evidence for a survival benefit with any therapy was absent until a recent trial demonstrated the utility of etoposide, doxorubicin, cisplatin, and mitotane (EDP-mitotane) [28]. Molecularly targeted therapies have been of interest [29-31], but none have yet proven successful. Of particular interest was a study demonstrating that adrenocortical carcinomas express cKit and/or the PDGF receptor at some frequency, but are unresponsive to single-agent imatinib [32].

Therefore, MTC and ACC require more effective therapy. As most MTCs have upregulated RET activity and pre-clinical studies using imatinib inhibit MTC cell proliferation and induce apoptosis, this drug has been appealing for treating this disease. ACC could also theoretically respond to imatinib, perhaps when combined with additional chemotherapy to allow for cytotoxicity. We therefore undertook a phase I dose-escalation trial of the combination of imatinib, dacarbazine, and capecitabine in advanced endocrine tumors, including predominantly patients with MTC and ACC.

**Methods**

**Inclusion criteria**

Men and women of all ethnic groups were eligible if they were > 16 years old with an ECOG performance status of 0–2 and any proven solid tumor for which no curative or standard treatment was available, regardless of prior therapy. Patients needed laboratory evidence of adequate hepatic, renal, and bone marrow function, as well as a negative pregnancy test (if applicable) and an agreement to use barrier contraception throughout therapy.

**Exclusion criteria**

Patients were ineligible if they had received chemotherapy or surgery within the last 3 weeks, or radiation within the last 4 weeks. Patients could not have received prior treatment with investigational agents within 28 days of study entry. Severe concurrent illness or ongoing pregnancy or lactation resulted in exclusion, as well. Patients with any other malignancy, except non-melanoma skin cancer or an MEN2-associated cancer, within the prior 5 years were also ineligible. Finally, patients could not be receiving warfarin during the study, though heparin products were allowed.

| Level | Imatinib | Dacarbazine | Capecitabine | Patients (N) | Dose reductions (N) | DLTs¹ (N and type) |
|-------|----------|-------------|--------------|--------------|---------------------|-------------------|
| −1    | 300 mg   | 250 mg/m2   | 500 mg/m2 BID| 6            | 0                   | 1 (fatigue)       |
| 1     | 400 mg   | 250 mg/m2   | 500 mg/m2 BID| 6            | 2                   | 9 (Dyspnea, Fatigue, Diarrhea, Dehydration, Nausea, Ocular Surface Disease, Insomnia) |
| 2     | 400 mg   | 330 mg/m2   | 750 mg/m2 BID| 6            | 1                   | 2 (Hypokalemia, platelets) |
| 3     | 400 mg   | 330 mg/m2   | 1000 mg/m2 BID| 0            | 0                   |                   |
| 4     | 600 mg   | 330 mg/m2   | 1000 mg/m2 BID| 0            | 0                   |                   |
| 5     | 800 mg   | 330 mg/m2   | 1000 mg/m2 BID| 0            | 0                   |                   |

¹: Dose levels specified for protocol therapy. 1: DLTs – dose-limiting toxicities.

**Table 2 Baseline patient characteristics**

| Characteristics | Number (%) |
|-----------------|------------|
| Age (Median)    | 52         |
| Gender          |            |
| Male            | 12 (60)    |
| Diagnosis       |            |
| MTC¹            | 7 (35)     |
| ACC²            | 5 (25)     |
| NET³            | 3 (25)     |
| Melanoma        | 1 (5)      |
| TCC⁴            | 1 (5)      |
| Prior therapy   | 19 (95)    |
| Surgery         | 16 (80)    |
| Radiation       | 10 (50)    |
| Chemotherapy    | 16 (80)    |

¹: MTC – medullary thyroid carcinoma; ²: ACC – adrenocortical carcinoma; ³: NET – neuroendocrine tumor; ⁴: Transitional cell carcinoma.

Characteristics of patients enrolled on the study. Total n = 20.
Table 3 Adverse events

| Toxicity                        | G1 | G2 | G3 | G4 | Total |
|---------------------------------|----|----|----|----|-------|
| Allergic rhinitis               | 2  | 1  | 0  | 0  | 3     |
| Alopecia                        | 2  | 0  | 0  | 0  | 2     |
| ALT<sup>1</sup>                 | 1  | 0  | 1  | 0  | 2     |
| Anorexia                        | 2  | 4  | 0  | 0  | 6     |
| AST<sup>2</sup>                 | 1  | 0  | 0  | 0  | 1     |
| Bilirubin                       | 1  | 0  | 0  | 0  | 1     |
| Cardiac ischemia                | 0  | 1  | 0  | 1  |       |
| Chest tightness                 | 1  | 0  | 0  | 0  | 1     |
| Constipation                    | 4  | 4  | 0  | 0  | 8     |
| Dehydration                     | 0  | 0  | 1  | 0  | 1     |
| Diarrhea                        | 5  | 2  | 1  | 0  | 8     |
| Distension                      | 0  | 0  | 1  | 0  | 1     |
| Dizziness                       | 2  | 0  | 0  | 0  | 2     |
| Dry mouth                       | 1  | 0  | 0  | 0  | 1     |
| Dry skin                        | 1  | 0  | 0  | 0  | 1     |
| Dysphagia                       | 1  | 0  | 0  | 0  | 1     |
| Dyspnea                         | 2  | 2  | 6  | 0  | 10    |
| Edema                           | 12 | 1  | 0  | 0  | 13    |
| Fatigue                         | 5  | 3  | 5  | 0  | 13    |
| Fever (no neutropenia)          | 1  | 0  | 0  | 0  | 1     |
| Flushing                        | 1  | 0  | 0  | 0  | 1     |
| Hand-foot syndrome              | 1  | 0  | 0  | 0  | 1     |
| Hemoglobin                      | 1  | 2  | 0  | 0  | 3     |
| Hypocalcemia                    | 1  | 0  | 0  | 0  | 1     |
| Hypokalemia                     | 2  | 0  | 2  | 0  | 4     |
| Hypomagnesemia                  | 1  | 0  | 0  | 0  | 1     |
| Insomnia                        | 2  | 5  | 1  | 0  | 8     |
| Mood alteration                  | 0  | 1  | 0  | 0  | 1     |
| Mucositis                       | 4  | 0  | 0  | 0  | 4     |
| Nausea                          | 4  | 6  | 1  | 0  | 11    |
| Neuropathy (sensory)            | 3  | 2  | 0  | 0  | 5     |
| Neutrophils                     | 0  | 2  | 1  | 0  | 3     |
| Ocular surface disease          | 1  | 1  | 0  | 0  | 3     |
| Ocular/visual                   | 2  | 0  | 0  | 0  | 2     |
| Pain                            | 12 | 6  | 1  | 0  | 19    |
| Palpitations                    | 1  | 0  | 0  | 0  | 1     |
| Platelets                       | 1  | 0  | 0  | 0  | 1     |
| Pleural effusion                | 1  | 0  | 0  | 0  | 1     |
| Pruritis                        | 1  | 0  | 0  | 0  | 1     |
| Rash                            | 6  | 0  | 0  | 0  | 6     |
| Rigors/chills                   | 2  | 0  | 0  | 0  | 2     |
| Sinus tachycardia               | 1  | 0  | 0  | 0  | 1     |
| Somnolence                      | 3  | 0  | 0  | 0  | 3     |
| Sweating                        | 1  | 0  | 0  | 0  | 1     |

(Continued)

Table 3 Adverse events

| Toxicity                        | G1 | G2 | G3 | G4 | Total |
|---------------------------------|----|----|----|----|-------|
| Taste alteration                | 5  | 4  | 0  | 0  | 9     |
| Upper respiratory infection     | 1  | 0  | 0  | 0  | 1     |
| Voice change                    | 2  | 0  | 0  | 0  | 2     |
| Vomiting                        | 2  | 2  | 0  | 0  | 4     |
| Watery eye                      | 1  | 0  | 0  | 0  | 1     |

Adverse events reported according to the Cancer Therapy Evaluation Program Common Toxicity Criteria, version 3.0. 1: ALT – alanine aminotransferase elevation; 2: AST – aspartate aminotransferase elevation.

Statistical considerations

Median progression-free survival (PFS) and overall survival (OS) were calculated by the Kaplan-Meier method. Follow-up was calculated from date of study enrollment until date of last contact. All statistical analyses were performed using SPSS version 21.0.
Results
Patient demographics
From January 2005 through September 2006, 21 patients were screened and 20 patients were enrolled. Their median age was 52 years (range 33–77 years) (Table 2). Two patients did not complete the first cycle of protocol therapy due to symptomatic or progressive disease, and were excluded from analysis for DLT. The patient population was enriched for patients with MTC and ACC, but also included patient with pancreatic neuroendocrine tumors, melanoma, and transitional cell carcinoma. All patients were metastatic at time of therapy initiation.

Dose escalation and maximum tolerated dose
An initial cohort of three patients was enrolled at dose level 1 (dacarbazine 250 mg/m2, capecitabine 1000 mg/m2 twice daily, and imatinib 400 mg) without observing a DLT. The next cohort of three patients was treated at dose level 2, with one patient experiencing grade 3 hypokalemia. An additional three patients were enrolled at this dose level, with one experiencing grade 3 thrombocytopenia. Therefore, three additional patients were enrolled at dose level 1, with all patients experiencing a grade 3 toxicity, including 2 patients with dyspnea and 2 with fatigue. When the next cohort of three patients was enrolled in dose level −1, a single patient experienced grade 3 fatigue. The final cohort of three patients enrolled in dose level −1 and experienced no DLT.

Safety
The most common toxicities for all cycles were fatigue and edema, each occurring in 65% of patients (Table 3). Edema was mostly grade 1, but 25% of patients described grade 3 fatigue during treatment. The most common grade 3 adverse event was dyspnea, with 30% of patients describing that symptom. Most treatment-related adverse effects were transient, and only one patient required dose reduction.

Tumor responses
Overall, 18 of 20 patients reached first restaging. The remaining two had expired from progressive disease. Of those 18 patients, 12 had progressive disease, 6 had stable disease, 1 had a minor response, and 1 had a confirmed partial response as best response to protocol therapy. Intriguingly, both of the responses were seen in patients with ACC, despite both of these patients being

| Patient | Diagnosis | PD at entry | Prior chemo | Prior surgery | Prior XRT | Chemo lines (n) | PFS (months) | OS (months) | Best protocol response |
|---------|-----------|-------------|-------------|--------------|-----------|----------------|--------------|-------------|-----------------------|
| 1       | NET¹      | 1           | 1           | 0            | 0         | 1              | 2.1          | 13.5        | PD                    |
| 2       | NET       | 1           | 0           | 0            | 0         | 0              | 0.8          | 2.3         | PD                    |
| 3       | MTC²      | 0           | 1           | 1            | 1         | 4              | 14.2         | 93.3        | SD                    |
| 4       | MTC       | 0           | 1           | 1            | 1         | 4              | 2.3          | 93.3        | SD                    |
| 5       | MTC       | 0           | 1           | 1            | 1         | 2              | 7.4          | 66.7        | SD                    |
| 6       | MTC       | 0           | 1           | 1            | 1         | 3              | 0.5          | 4.1         | PD                    |
| 7       | MTC       | 1           | 1           | 1            | 1         | 1              | 2.3          | 20.3        | PD                    |
| 8       | MTC       | 1           | 1           | 1            | 1         | 3              | 2.2          | 7.1         | PD                    |
| 9       | NET       | 1           | 1           | 0            | 1         | 3              | 0.5          | 0.5         | Death                |
| 10      | ACC³      | 1           | 1           | 1            | 0         | 1              | 6.4          | 17.5        | MR                    |
| 11      | MTC       | 0           | 0           | 0            | 1         | 0              | 7.7          | 88.6        | PD                    |
| 12      | ACC       | 1           | 1           | 1            | 1         | 5              | 2.4          | 2.4         | Death                |
| 13      | TCC⁴      | 1           | 1           | 1            | 0         | 6              | 2.6          | 9.1         | PD                    |
| 14      | ACC       | 1           | 1           | 1            | 0         | 2              | 8.8          | 39.5        | PR                    |
| 15      | MTC       | 0           | 0           | 1            | 0         | 0              | 6.3          | 82.0        | SD                    |
| 16      | ACC       | 1           | 1           | 1            | 0         | 2              | 1.6          | 80.7        | PD                    |
| 17      | ACC       | 1           | 0           | 1            | 0         | 0              | 1.7          | 79.5        | PD                    |
| 18      | Melanoma  | 1           | 1           | 1            | 1         | 1              | 2.1          | 7.8         | PD                    |
| 19      | ACC       | 1           | 1           | 1            | 0         | 2              | 2.1          | 13.4        | PD                    |
| 20      | ACC       | 1           | 1           | 0            | 0         | 1              | 2.0          | 18.6        | PD                    |

Table 4 Patient outcomes

¹NET – neuroendocrine tumor; ²MTC – medullary thyroid carcinoma; ³ACC – adrenocortical carcinoma; ⁴TCC – transitional cell carcinoma. PD – progressive disease; SD – stable disease; MR – minor response; PR – partial response.

XRT – radiation therapy; Chemo lines – number of prior chemotherapies.
previously treated with standard therapy. The remaining 5 patients with ACC experienced progressive disease. No responses were seen in those patients with MTC, but 4 of 5 patients experienced stable disease (Table 4). However, all 4 patients entered the study with stable disease. With a median follow-up of 82 months, the median PFS was 2.3 months (95% CI 2–2.7), with median OS of 18.6 months (95% CI 8.8–28.4). Given the heterogeneity of the patient population, patient-level survival information is given in Table 4.

Discussion

In this phase I study, we have evaluated the safety of the combination of dacarbazine, capecitabine, and imatinib in metastatic endocrine cancers. The recommended dose regimen for a phase II trial is dacarbazine 250 mg/m2 daily on day 1–3, capecitabine 500 mg/m2 twice daily on days 1–14, and imatinib 300 mg daily on days 1–21 of a 21-day cycle. Dose-limiting toxicities most frequently included fatigue, dyspnea, and minor electrolyte and blood count abnormalities. The combination was otherwise tolerated well.

We also revealed evidence of activity of this regimen in ACC, even in the context of pretreated, refractory disease, a situation for which there are very limited effective therapies. Impact on overall survival is challenging to assess in the setting of a heterogeneous and uncontrolled patient population with respect to previous treatments, however, and overall survival was no better among the two responders than among the five non-responders.

Since this trial was initiated, multiple studies have investigated the in vitro and in vivo activity of imatinib-based regimens in MTC. Early studies of the in vitro effects demonstrated RET inhibition and death of oncogene-addicted MTC cells [14,33], but these studies demonstrated successful RET inhibition only at serum concentrations that could not be achieved with tolerable doses of imatinib, and subsequent clinical trials of imatinib monotherapy revealed no responses in MTC [32,34]. In one of these trials of imatinib monotherapy, patients with ACC were included as well, without evidence of clinical response [32]. Additional investigation of this agent in ACC, alone or in combination with cytotoxic chemotherapy has otherwise been lacking, making our combination entirely novel.

Conclusion

We present here the results of phase I trial of a combination of targeted therapy using imatinib with cytotoxic chemotherapy using capecitabine and dacarbazine in patients with advanced endocrine malignancies. Responses were rare, but occurred exclusively in patients with ACC, a cancer with limited effective therapies. These data should prompt consideration of a phase II trial of such a combination in this disease, given the paucity of other options. Alternatively, our hope is that these results will promote a deeper understanding of the disease biology in those patients who responded, allowing for the insightful and rational development of future targeted therapies.
Mutation of the RET protooncogene in sporadic medullary thyroid carcinoma. *Genes Chromosoms Cancer* 1995, 12(3):209–212.

8. Hofstra RM, Landsvater RM, Cecchini I, Stulp RP, Stelwagen T, Luo Y, Pasini B, Hoppener JW, van Amstel HK, Romano G, Lips CM, Buys CHCM: A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. *Nature* 1994, 367(6466):575–576.

9. Zedenius J, Larsson C, Bergholm U, Boven J, Svensson A, Hallengren B, Grimmelius L, Backdahl M, Weber G, Wallin G: Mutations of codon 918 in the RET proto-oncogene correlate to poor prognosis in sporadic medullary thyroid carcinomas. *J Clin Endocrinol Metab* 1995, 80(10):3088–3090.

10. Asi N, Iwashita T, Matsuoka M, Takahashi M: Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. *Mol Cell Biol* 1995, 15(3):1613–1619.

11. Xing S, Smirnakis PA, Ogletree MJ, Trosko JE, Mazzaferri EL, Jhiang SM: Characterization of ret oncogenic activation in MEN2 inherited cancer syndromes. *Endocrinology* 1996, 137(5):1512–1519.

12. Santoro M, Calmonaggio F, Romano A, Bottaro DP, Dathan NA, Grieco M, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ, Schlumberger MJ: Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer. *J Clin Oncol* 2011, 29(2):215–221.

13. Marshall GM, Peaston AE, Hocker JE, Smith SA, Hansford LM, Tobias V, Norris JH, Ackerstein A, Salmon A, Sella A, Slavin S. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. *Endocr Relat Cancer* 2006, 13(2):535–540.

14. Reeves MJ, Plaza Menacho I, Schepers H, Drenth-Diephuis LJ, Osinga J, van der Bijl AM, de Vries WC, Pinedo HM: Mutations of codon 918 in the RET proto-oncogene associated with multiple endocrine neoplasia 2B RET in neuroblastoma cells alters cell adhesion in vitro, enhances metastatic behavior in vivo, and activates Jun kinase. *Cancer Res* 1997, 57(23):599–605.

15. Cohen MS, Hussain HB, Moley JF: Activity of RET as a dominant transforming gene by germline mutations of MEN 2A and MEN 2B. *Science* 1995, 267:381–383.

16. Marshall GM, Peaston AE, Hocker JE, Smith SA, Hansford LM, Tobias V, Norris JH, Ackerstein A, Salmon A, Sella A, Slavin S. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. *Endocr Relat Cancer* 2006, 13(2):535–540.

17. Schlumberger M, Abdelmoumene N, Delisle MJ, Couette JE: Treatment of advanced medullary thyroid carcinoma with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. The Groupe d'Etude des Tumeurs a Calcitonine (GETC). *Br J Cancer* 1995, 71(2):363–365.

18. Di Bartolomeo M, Bajetta E, Bochicchio AM, Caragni C, Somma L, Mazzafaro V, Visini M, Gelli V, Turnolo S, Ballatore P: A phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours. A study by the Italian Trials in Medical Oncology (I.T.M.O.) Group. *Ann Oncol* 1995, 6(1):77–79.

19. Xing S, Smirnakis PA, Ogletree MJ, Trosko JE, Mazzaferri EL, Jhiang SM: Characterization of ret oncogenic activation in MEN2 inherited cancer syndromes. *Endocrinology* 1996, 137(5):1512–1519.

20. Pihlajaniemi T, Riekkinen P, Torssö E, Knuutila S, Kallioniemi OP, Aittomäki K, Sipari N, Virtanen I, Sistonen L, Aittomäki-Kallio V: Molecular markers and the pathogenesis of adrenocortical cancer. *Oncologist* 2008, 13(5):548–561.